EN DE
Watch Medicure Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medicure Inc (MPH) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Medicure Inc stock C$3.39, price C$3.70, that is 8.4% below the price, quality 52 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA58469E4085

MI Medicure Inc logo Thin data Nov 10, 2026

Medicure Inc

MPH · V
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Low debt
Fair value C$3.39 · Fairly valued
Quality 52/100
Expensive Growth (revenue 5y +20.0 %/yr in CAD)
Mixed vs. peers (5/11)
Loss-making · -23.2% net margin (TTM)
Negative free cash flow
Narrow moat 9/100
Thin data
Estimate
Watch Medicure Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$5.22 C$0.6300 Fair Value C$3.39 Jun 2019 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range C$0.6300 – C$5.22 · fair‑value band C$2.54 – C$4.24 · the C$3.70 price screens above the C$3.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Medicure in your weekly email

Every Wednesday you see whether Medicure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.

Show moreShow less

The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.

In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Stock analysis

Medicure Inc (MPH) currently trades at C$3.70, while our estimate is C$3.39, so the stock looks roughly fairly valued today (gap 9.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$2.54 (bear) to C$4.24 (bull), the price of C$3.70 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Medicure Inc reported revenue of C$28.9M in FY2025 versus C$21.7M in FY2021, a compound +7.3%/yr. Reported net income was −C$7.1M in FY2025.

Key figures

Market cap C$39.5M (≈ $27.8M) Micro · P/S ratio 1.43 · EPS (TTM) C$−0.7100 · Net margin −23.2% · Return on equity −49.9% · Return on assets (EBIT) −7.5% (5-year average) · Operating margin −18.2% · Revenue (TTM) C$32.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 17% below its 52-week high and 311% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −8%, MPH screens cheaper than that median.

Fair Value

Bear C$2.54 Fair Value C$3.39 Bull C$4.24
Price C$3.70 · Downside -8.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 35
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 25
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 90
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+31.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.0%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−62.8% (2020) → −23.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MPH, get fair value alerts →

Compare Medicure Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −8.4% · Above median
Profitability
Return on assets −28.5% · Bottom 25%
Net margin (12 months) −23.2% · Bottom 25%
Operating margin (12 months) −18.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 11.4% · Above median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 3.06× · Pricier than median
P/S (12 months) 1.23× · Cheaper than median
PEG 0.17× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 18
FUTURE (revenue growth)57 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs MPH
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs MPH
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs MPH
Haleon plc HLN $9.06 $8.62 −5% vs MPH
Merck KGaA MRK €149.35 €109.18 −27% vs MPH
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs MPH
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs MPH
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs MPH
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs MPH
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs MPH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medicure Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medicure Inc Fair Value". https://www.fairvalue-calculator.com/stock/MPH

Frequently asked questions

Is Medicure Inc (MPH) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is C$3.39 versus a price of C$3.70, about 8% lower (fairly valued).
What is the fair value of MPH?
Our estimate for Medicure Inc is C$3.39 (as of Nov 10, 2026), built from audited fundamentals. The current price: C$3.70.
What is the quality score of MPH?
Medicure Inc has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicure Inc (MPH)?
Our calculated price target is the estimate of C$3.39 (as of Nov 10, 2026). Cautious scenario C$2.54, optimistic scenario C$4.24. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Medicure Inc stock forecast for 2026?
Our estimate puts fair value at C$3.39, about 8% lower versus a price of C$3.70 (fairly valued). Cautious scenario C$2.54, optimistic scenario C$4.24. The calculation is refreshed regularly with new filings.
What is the revenue of Medicure Inc (MPH)?
Medicure Inc reported trailing-twelve-month revenue of about C$32.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Medicure Inc (MPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicure Inc it is C$3.39 per share (as of Nov 10, 2026), against a price of C$3.70.
Is Medicure Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MPH trades above its calculated fair value: price C$3.70, fair value C$3.39, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MPH?
No. The price is what the market pays today (C$3.70); the fair value is what the company's own numbers justify (C$3.39). For Medicure Inc the two are C$0.3100 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicure Inc worth?
The market values Medicure Inc at about C$39.5M (market capitalisation, as of Nov 10, 2026). Per share that is C$3.70; our models calculate a fair value of C$3.39 per share.
What do the bullish and bearish scenarios say about MPH?
Our models span a range for Medicure Inc: cautious scenario C$2.54, base C$3.39, optimistic C$4.24 per share (as of Nov 10, 2026, price C$3.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MPH?
The PEG ratio of Medicure Inc is 0.17 (P/E divided by earnings growth, as of Nov 10, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Medicure Inc (MPH)?
Balance-sheet figures for Medicure Inc (as of Nov 10, 2026): return on equity −49.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is MPH from its 52-week high?
Medicure Inc trades at C$3.70, about 17% below its 52-week high of C$4.44 and 311% above the low of C$0.9000 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of C$3.39 is for.
Which stocks are comparable to Medicure Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicure Inc stock attractive at the current price?
The data as of Nov 10, 2026: price C$3.70, calculated fair value C$3.39 (−8%), Quality Score 52/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Medicure Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicure Inc (MPH)?
The closing price on Nov 10, 2026 was C$3.70. Our estimate is C$3.39, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicure Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Medicure Inc

How large is the market capitalisation of Medicure Inc (MPH)?
The market capitalisation of Medicure Inc is C$39.5M (≈ $27.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicure Inc (MPH)?
The price-to-sales ratio of Medicure Inc is 1.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medicure Inc (MPH)?
Earnings per share at Medicure Inc are C$−0.7100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medicure Inc (MPH)?
The net margin of Medicure Inc is −23.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medicure Inc (MPH)?
The return on equity (ROE) of Medicure Inc is −49.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicure Inc (MPH)?
On an EBIT basis the return on assets of Medicure Inc is −7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicure Inc (MPH)?
The operating margin of Medicure Inc is −18.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicure Inc (MPH)?
Revenue at Medicure Inc is growing +11.4% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medicure Inc (MPH)?
Earnings per share at Medicure Inc are growing +710% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medicure Inc (MPH) generate?
The free cash flow of Medicure Inc is −C$560K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Medicure Inc (MPH) hold?
Medicure Inc holds more cash than debt, C$5.8M net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Medicure Inc in the live analysis

One click puts Medicure Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.